New Guidelines to Evaluate the Response to Treatment in Solid Tumors
Patrick Therasse, Susan G. Arbuck, Elizabeth A. Eisenhauer, Jantien Wanders, Richard S. Kaplan, Larry Rubinstein, Jaap Verweij, Martine M. Van Glabbeke, Allan T. van Oosterom, Michaele C. Christian, Steve G. Gwyther
JNCI Journal of the National Cancer Institute · 2000 · 15,678 citations
No retraction on record in OpenAlex.Check Crossref now
Cite this paper
Therasse, P., Arbuck, S. G., Eisenhauer, E. A., Wanders, J., Kaplan, R. S., Rubinstein, L., Verweij, J., Glabbeke, M. M. V., Oosterom, A. T. van, Christian, M. C., & Gwyther, S. G. (2000). New guidelines to evaluate the response to treatment in solid tumors. JNCI Journal of the National Cancer Institute, 92(3), 205–216. https://doi.org/10.1093/jnci/92.3.205
In text: (Therasse et al., 2000)
Ask a question about this research
One question, free, no account. Anchorcite finds the papers, checks each against Crossref and links every sentence of the answer to the passage it comes from.
Abstract
Anticancer cytotoxic agents go through a process by which their antitumor activity-on the basis of the amount of tumor shrinkage they could generate-has been investigated. In the late 1970s, the International Union Against Cancer and the World Health Organization introduced specific criteria for the codification of tumor response evaluation. In 1994, several organizations involved in clinical research combined forces to tackle the review of these criteria on the basis of the experience and knowledge acquired since then. After several years of intensive discussions, a new set of guidelines is ready that will supersede the former criteria. In parallel to this initiative, one of the participating groups developed a model by which response rates could be derived from unidimensional measurement of tumor lesions instead of the usual bidimensional approach. This new concept has been largely validated by the Response Evaluation Criteria in Solid Tumors Group and integrated into the present guidelines. This special article also provides some philosophic background to clarify the various purposes of response evaluation. It proposes a model by which a combined assessment of all existing lesions, characterized by target lesions (to be measured) and nontarget lesions, is used to extrapolate an overall response to treatment. Methods of assessing tumor lesions are better codified, briefly within the guidelines and in more detail in Appendix I. All other aspects of response evaluation have been discussed, reviewed, and amended whenever appropriate.
Related papers
- Bias in meta-analysis detected by a simple, graphical test1997
- Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement2009
- Quantifying heterogeneity in a meta‐analysis2002
- Intraclass correlations: Uses in assessing rater reliability.1979
- Comparing the Areas under Two or More Correlated Receiver Operating Characteristic Curves: A Nonparametric Approach1988
Metadata from OpenAlex (CC0). Citations are generated from the published record.